ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0726

Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review

Emma Neary1, Katie Healey2, Marie Clements-Baker3, Jean-Paul Makhzoum4 and Arielle Mendel5, 1McGill University, Montreal, QC, Canada, 2Memorial University of Newfoundland, St. John's, NL, Canada, 3Queen's University, Kingston, ON, Canada, 4Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, 5McGill University Health Centre, Montreal, QC, Canada

Meeting: ACR Convergence 2024

Keywords: ANCA, ANCA associated vasculitis, Eye Disorders, meta-analysis, Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Ocular manifestations are common in ANCA-associated vasculitides (AAV), with orbital inflammatory disease (OID) representing a significant subset. Despite being a vision-threatening complication, OID remains a significant therapeutic challenge. The aim of this systematic review was to evaluate the efficacy and safety of interventions for AAV-associated OID.

Methods: We searched for clinical trials, case-control studies, observational studies and case series ( >=5 patients) of adult patients undergoing therapy for AAV-associated OID within Embase Classic + Embase, MEDLINE(R) via Ovid, Web of Science Core Collection, Clinicaltrials.gov, and Cochrane Central Register of Controlled Trials without language or date restrictions. Included studies were required to clearly report on types and dosing of therapies used and clinical response after at least 1 month of follow up or later. The primary outcome was clinical response, defined as any improvement in signs and/or symptoms, up to and including the achievement of clinical remission (complete response). Secondary outcomes included clinical remission, relapse, sustained remission ( >6 months) and serious adverse events. Two reviewers independently screened for relevant records and critically appraised included articles using the Newcastle Ottawa Scale (NoS) checklist. We performed a qualitative synthesis of results from eligible articles. We also performed a meta-analysis of proportions for any outcomes with sufficient clinical homogeneity using a random effects model and restricted maximum likelihood approach. Analyses were conducted using Stata SE (v18.0).

Results: The search strategy identified 1001 unique studies. After title and abstract screening, we included 119 (12%) in the full-text review, of which 18 (1.8%) met eligibility criteria and were included, representing 277 patients (Table 1). 17/18 studies had NoS scores of 5 or higher. Study designs included retrospective cohort (n=14) and case series (n=4). Treatment regimens varied across and within studies: 13 studies included patients who received rituximab (RTX), 10 studies included patients who received cyclophosphamide (CYC), 7 studies included patients who received RTX plus another immunosuppressant (IS), 11 studies included patients who received conventional IS, and 7 studies included patients who underwent surgery. The most frequent time point for reporting treatment outcomes was 6 months (5 studies, 4 of RTX and 1 of RTX + IS) (Table 2). Of these, all studies (5/5) observed some clinical response in 100% of individuals. With RTX, clinical remission/complete response at 6 months was achieved in 84% of individuals (95% CI 72%-95%, z=14.35, p< 0.001) (Figure 1).

Conclusion: Studies have reported a variety of therapies for AAV-associated OID. Pooled estimates showed that over three quarters of individuals achieved clinical remission with RTX at 6 months, and qualitatively, high rates of remission were reported for RTX + conventional IS. Our results emphasize the necessity of larger, prospective studies examining treatments for AAV-associated OID.

Supporting image 1

Table 1: Characteristics of included studies (n=18) and patients (n=277) receiving therapies for AAV-associated OID

Supporting image 2

Table 2: Outcomes of included studies (n=18) and patients (n=277) receiving therapies for AAV-associated OID

Supporting image 3

Figure 1: Forest diagram of studies including patients undergoing Rituximab and glucocorticoid therapy for AAV-associated OID, with clinical remission reported at 6 months follow-up


Disclosures: E. Neary: None; K. Healey: None; M. Clements-Baker: AbbVie/Abbott, 1, Boehringer-Ingelheim, 1, 6, Otsuka, 1, 6, UCB, 1; J. Makhzoum: Abbvie, 5, Janssen, 6, Novartis, 5, Otsuka, 1, 6; A. Mendel: None.

To cite this abstract in AMA style:

Neary E, Healey K, Clements-Baker M, Makhzoum J, Mendel A. Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/management-of-anca-vasculitis-associated-orbital-inflammatory-disease-a-systematic-literature-review/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/management-of-anca-vasculitis-associated-orbital-inflammatory-disease-a-systematic-literature-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology